Responses and adverse effects of carboplatin-based chemotherapy for pediatric intracranial germ cell tumors.
10.3345/kjp.2011.54.3.128
- Author:
Suntae JI
1
;
Hee Won CHUEH
;
Ju Youn KIM
;
Su Jin LIM
;
Eun Joo CHO
;
Soo Hyun LEE
;
Keon Hee YOO
;
Ki Woong SUNG
;
Hong Hoe KOO
Author Information
1. Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. hhkoo.koo@samsung.com
- Publication Type:Original Article
- Keywords:
Intracranial germ cell tumor;
Carboplatin;
Adverse effects
- MeSH:
Carboplatin;
Creatinine;
Disease-Free Survival;
Germ Cells;
Hearing;
Humans;
Male;
Neoplasms, Germ Cell and Embryonal;
Neutropenia;
Retrospective Studies
- From:Korean Journal of Pediatrics
2011;54(3):128-132
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: Cisplatin-based chemotherapy has been commonly used for the treatment of intracranial germ cell tumors (IC-GCTs). However, this treatment exhibits some adverse effects such as renal problems and hearing difficulty. Carboplatin-based chemotherapy was administered to pediatric patients with IC-GCTs from August 2004 at the Samsung Medical Center. In this study, we assessed the responses and adverse effects of carboplatin-based chemotherapy in pediatric IC-GCTs patients according to the risk group, and compared the results with those of the previous cisplatin-based chemotherapy. METHODS: We examined 35 patients (27 men and 8 women) diagnosed with IC-GCTs between August 2004 and April 2008 and received risk-adapted carboplatin-based chemotherapy at the Samsung Medical Center. Patients were divided into either low-risk (LR) or high-risk (HR) groups and a retrospective analysis was performed using information from the medical records. RESULTS: Although hematological complications were common, hearing difficulties or grade 3 or 4 creatinine level elevation were not observed in patients who underwent carboplatin-based chemotherapy. The frequency of febrile neutropenia did not differ between the risk groups. The overall survival was 100% and event-free survival (EFS) was 95.7%. The EFS rate was 100% in the LR group and 90% in the HR group, respectively. CONCLUSION: Despite their common occurrence in high-risk patients, no lethal hematological complications were associated with carboplatin-based treatment. The current carboplatin-based chemotherapy protocol is safe and effective for the treatment of pediatric patients with IC-GCTs.
